Enanta Pharmaceuticals has presented research data on EDP-721 for the treatment of hepatitis B virus. Trials have shown the efficacy of further developing EDP-721 for oral administration to provide a functional treatment for hepatitis. The Phase 1 study is scheduled to begin in mid-2021.